Roche has won a nod from FDA for a new diagnostic for individual blood donation testing. The Basel-Switzerland-based company’s cobas Babesia test is for use on the cobas 6800 8800 system.

In diagnostics these days, “a lot of people are after plasma,” reports Jim Averso, vice president, sales and marketing, of I.W. Tremont.

Bio-Techne said recently that its fiscal 2020 first quarter revenues rose 12 percent year over year, driven by growth in each of its business segments.

The National Institutes of Health has awarded researchers at the University of Virginia a $2.7 million grant to investigate how variation in a specific gene, called ID3, influences atherosclerosis.

Genialis recently announced a comarketing agreement with Thermo Fisher Scientific on data analysis for RNA sequencing.

Exact Sciences reported after the close of the market recently that its third quarter revenues rose 85 percent year over year, thanks to an 89 percent increase in testing volumes for its Cologuard colorectal cancer screening test.

LexaGene said recently that it has closed a previously announced financing round, grossing C$6.7 million (US$5.1 million).

Korean rare disease diagnostics firm 3billion said this week that it has raised $10 million in a Series B financing round.

Illumina and Qiagen recently announced a 15-year partnership to develop next-generation sequencing-based in vitro diagnostic kits, including companion diagnostics.

Genomic services provider Novogene has signed an agreement to develop a companion diagnostic for a cancer drug under development at Chipscreen Biosciences, the Chinese companies said today.

The global immunoassay market is projected to grow at a CAGR of 5.9% from 2019 to reach USD 19.76 billion by 2025...

Diagnostics developer DiamiR said today that it has received an additional $345,000 in grant funding from the National Institute on Aging to develop a microRNA-based test for early-stage Alzheimer's disease.

Thermo Fisher Scientific today priced an underwritten offering of a series of euro- and dollar-denominated senior notes, in an aggregate principal amount of $5.7 billion.

Roche announced today its cobas Babesia blood test for individual blood donation testing has received marketing approval from the US Food and Drug Administration.

PerkinElmer said after the close of the market on Tuesday that it has entered into an agreement for a new $1 billion unsecured revolving credit facility available through Sept. 17, 2024.